EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The essentials—measurable residual disease in hematopoietic neoplasms: current testing landscape and future directions

Savanah D Gisriel iD, Alexa Siddon iD

American Journal of Clinical Pathology · 06.07.2026 · 166 (1)

DOI: 10.1093/ajcp/aqag079 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 09.07.2026. Verfasst von Savanah D Gisriel und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, United States. Hauptthemen laut MEDLINE: Neoplasm, Residual, Hematologic Neoplasms. Die Arbeit nennt 65 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Measurable residual disease (MRD) analysis, also known as minimal residual disease analysis, has become an essential component of routine clinical management in many hematopoietic neoplasms. Measurable residual disease status in the absence of morphologic disease holds prognostic value and can acutely affect treatment decisions.

Methods

Measurable residual disease monitoring is described in acute leukemia, multiple myeloma, and chronic lymphocytic leukemia. We discuss the approach to MRD assessment of these hematologic neoplasms using flow cytometry and molecular techniques.

Results

The appropriate use of available ancillary techniques is crucial to assess patients for MRD. Interpreting these results in the appropriate clinical context is challenging and often requires expertise. Incorporating the results into disease management is critical for improved outcomes.

Conclusions

Consensus guidelines on MRD assessment in hematopoietic neoplasms continue to evolve. Further, emerging technologies and laboratory availability are important practical considerations for pathologists who are implementing MRD analysis. From this review, pathologists can gain an anecdotal perspective on the application and interpretation of advanced studies to assess the MRD status of patients with hematopoietic malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm, ResidualHematologic NeoplasmsHumansFlow CytometryPrognosis

Stichwörter der Autor:innen

PCRflow cytometryhematopathologymeasurable residual diseaseminimal residual diseasemolecular diagnostics

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, United States.
  • Departments of Pathology and Laboratory Medicine, Yale School of Medicine, New Haven, CT, United States.

ORCID-Profile: Savanah D Gisriel, Alexa Siddon

Zitieren

APA

Gisriel, S. D., & Siddon, A. (2026). The essentials—measurable residual disease in hematopoietic neoplasms: current testing landscape and future directions. American Journal of Clinical Pathology, 166(1). https://doi.org/10.1093/ajcp/aqag079

Vancouver

Gisriel SD, Siddon A. The essentials—measurable residual disease in hematopoietic neoplasms: current testing landscape and future directions. American Journal of Clinical Pathology. 2026;166(1). doi:10.1093/ajcp/aqag079

BibTeX
@article{Gisriel2026,
  author = {Gisriel, Savanah D and Siddon, Alexa},
  title = {The essentials—measurable residual disease in hematopoietic neoplasms: current testing landscape and future directions},
  journal = {American Journal of Clinical Pathology},
  year = {2026},
  volume = {166},
  number = {1},
  doi = {10.1093/ajcp/aqag079}
}
Kostenlos starten →